
Patients died cold and uncared for: Health Ombud exposes collapse of psychiatric care in Northern Cape
The mental health hospital operated without electricity for year, leaving life-saving equipment useless.
Leadership failures and staff shortages caused the systemic collapse of the patient care system.
The Health Ombud found that two psychiatric patients died and one was left permanently bedridden due to neglect and poor care.
Northern Cape Mental Health Hospital went without electricity for a year, leaving life-saving equipment unusable and patients exposed to extreme temperatures.
These are some of the findings in a damning report by Health Ombud Professor Taole Mokoena, who investigated the treatment, complications and deaths of psychiatric patients at the Northern Cape Mental Health Hospital and the Robert Mangaliso Sobukwe Hospital.
The report cites leadership failures, staff shortages and collapsing infrastructure as the main reasons for the breakdown in patient care.
Emergency machines stood useless as they had not been charged. Calls for help could not go out as the phone lines were down.
Some patients died. Others were sent out in critical condition. One will never walk again.
The investigation followed a complaint made by Health Minister Aaron Motsoaledi in October last year.
The report details how systemic neglect, infrastructure collapse, poor staffing and lack of leadership directly led to suffering, medical complications and death.
Four psychiatric patients were closely examined in the report – two died, one suffered permanent disability and another experienced complications due to poor monitoring.
In his report Mokoena states:
The general care provided was substandard, and patients were not attended to in a manner consistent with the nature and severity of their health condition.
Taole Mokoena
The situation was made worse by a yearlong power outage at Northern Cape Mental Health Hospital, caused by cable theft and vandalism.
While neighboring hospitals had their power restored within days, this one was left without electricity due to delays in the provincial department's supply chain processes.
'Because of the lack of electricity, resuscitation equipment could not be used, heating and cooling systems failed, and patients had to endure extreme weather conditions without proper clothing or bedding.
The report
What happened
Cyprian Mohoto was transferred to Robert Mangaliso Sobukwe Hospital on 13 July last year after he experienced serious complications. A chest X-ray revealed that he had pneumonia, but this was never treated. For three days, his deteriorating condition was ignored by both nurses and doctors. He died on 16 July in the emergency unit.
Tshepo Mdimbaza was found unresponsive in his bed at Northern Cape Mental Health Hospital on 3 August. When staff attempted to resuscitate him, they discovered that the equipment was not prepared or functional. His vital signs had not been properly monitored. A post-mortem found he had died from 'exposure to the elements'.
John Louw, a patient at Northern Cape Mental Health Hospital, suffered a brain injury known as a subdural haemorrhage. After emergency surgery, including a craniotomy and craniectomy, was performed on 7 July and 23 July respectively, complications have left him permanently bedridden.
Petrus de Bruin collapsed in ward M2 at Northern Cape Mental Health Hospital on 30 July and was transferred to Robert Mangaliso Sobukwe Hospital's Emergency Centre. He was stabilised and admitted for hypoglycaemia. While emergency care was appropriate, nursing monitoring was inadequate.
The report highlighted a deep leadership crisis and operational failure at both facilities.
At Northern Cape Mental Health Hospital, there was no emergency preparedness, collapsing infrastructure, poor medicine control, a shortage of staff and a lack of proper record keeping, the report revealed.
The Ombud found that:
The clinical manager had written to the acting head of the provincial department of health, warning about the harmful conditions patients were facing, but no action was taken.
At Robert Mangaliso Sobukwe Hospital, the problems included overcrowding, missing patient files, poor supervision of nurses and staffing shortages across all departments.
'Leadership instability in the Northern Cape provincial department of health negatively affected service delivery, patient safety and the overall quality of care,' said Mokoena.
Recommendations
The Ombud called for urgent action to fix the broken system. This includes:
'This level of systemic collapse must never be allowed to happen again in our health system,' Mokoena added.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
41 minutes ago
- Yahoo
Recovery.com Acquires Recovery Brands Care Navigation Platform from American Addiction Centers in Eight-Figure Deal to Expand Access to Care
Strategic acquisition of premier sites doubles reach, solidifying leading market position and accelerating access to trusted treatment options for millions MADISON, Wis., Aug. 07, 2025 (GLOBE NEWSWIRE) -- and American Addiction Centers (AAC) today announced the sale and transition of several leading addiction treatment care navigation websites from AAC subsidiary Recovery Brands to The sites include and The transition reflects a commitment from both parties to help individuals and families find addiction treatment options that meet their individual needs, and a recognition that digital platforms are often the first step in that journey. For the acquisition represents an opportunity to expand its impact and further strengthen the tools and resources available to individuals navigating the treatment landscape. 'We've spent many years and invested millions of dollars building the best place on the internet to find mental health and addiction treatment and by bringing these websites under our ownership our impact and reach essentially doubled overnight,' said Ben Camp, CEO of 'We've long believed we were a perfect home for these websites, and I'm so glad that AAC's leadership decided the time was right to sell. This is a major win for patients and for the industry.' 'This transaction reflects AAC's continued commitment to expanding access to lifesaving care through mission-aligned partnerships,' said Dr. David Hans, Co-CEO of American Addiction Centers. 'Our vision as a company is to foster a world free from the stigma of addiction, where quality treatment and support are accessible for all.' 'Recovery Brands has been a trusted digital front door to treatment for millions, and this strategic sale enables to scale that impact even further—while allowing AAC to sharpen its focus on delivering high-quality, patient-centered care across our facilities nationwide,' said Ellen-Jo Boschert, Co-CEO of American Addiction Centers. The sale marks a meaningful step forward for both organizations as access to treatment remains critical. About in 2017, is the leading global platform for finding trusted mental health and addiction treatment. Each month, millions of people engage with us across our websites and social media platforms to search 20,000+ providers, compare treatment center details and reviews, read helpful recovery resources, interact with community content, and connect directly with the right treatment for them. We list all treatment options on our care navigation websites at no cost, while providing an ethical, best-in-class advertising platform for LegitScript-certified addiction treatment and mental health providers. Learn more at About American Addiction Centers At American Addiction Centers (AAC), we believe in the power of recovery. As a national leader in substance use disorder treatment, we provide compassionate, evidence-based inpatient and outpatient care for individuals struggling with addiction and mental health disorders. Our mission is to restore hope and empower individuals and families, offering a foundation for lasting recovery that transforms lives. We envision a world free from the stigma of addiction, where high-quality care is accessible to all. Learn more at Media Contacts: Jeremy Tunis, Senior Advisor, Public Affairs and Communications American Addiction Centers Joy Sutton, VP of Brand and Communications jsutton@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data


Forbes
an hour ago
- Forbes
Amid Turbulence, Global Health Innovations Offer Glimmers Of Hope
When (RED), the organization that I lead, first met Concillia, she was on the brink of death. She was living with HIV, but wasn't receiving treatment. She weighed under 100 lbs. and could barely feed herself, let alone look after her young daughter. Access, stigma, and a lack of education kept her from the life-saving medicine she desperately needed. Then Concillia was connected to a support group of other people living with HIV and began taking antiretroviral medicine. In just 90 days, she was 'resurrected' from death's door. Full of hope and purpose, she soon gave birth to an HIV-free daughter and became a healthcare worker in Lusaka, Zambia to help women just like her. She's living proof that innovation, combined with access, saves lives. Today, amid the global health chaos and crisis imposed by the United States' abrupt dismantling of USAID, science and innovation are forging new miracles. From breakthrough medicines to AI-powered tools, here are some of the next wave solutions that could accelerate the fight against preventable diseases. The Promise Of Lenacapavir While it seldom makes headlines, AIDS is still a deadly crisis in many parts of the world. Roughly every minute someone dies of AIDS-related causes. Today, more people live with HIV than there are people in California. And by the time you're done reading this piece, 10 people will have acquired the virus. One of the best ways to combat AIDS is to prevent new infections in the first place. If you achieve that, you lower the transmission rates and stop it from spreading. That's why the new long-acting injectable medicine lenacapavir from Gilead Sciences is so promising. Earlier this year, the Food and Drug Administration (FDA) approved the medicine for pre-exposure prophylaxis (PrEP) to reduce the risk of adults and adolescents acquiring HIV. Lenacapavir offers individuals protection against HIV for up to six months. Previously, those who were at-risk of acquiring HIV relied on daily PrEP pills that often carried privacy, stigma, and adherence challenges. The medicine's real potential is in places like Sub-Saharan Africa where two-thirds of all new HIV infections originate. Earlier this month, Gilead Sciences and the Global Fund to Fight AIDS, TB and Malaria (Disclosure: (RED) donates money to the Global Fund) announced a landmark partnership that will supply the long-acting prevention medicine to low-income countries. Under the agreement, Gilead Sciences will supply the Global Fund enough doses to reach up to 2 million people over three years. 'This is not just a scientific breakthrough — it's a turning point for HIV/AIDS,' Peter Sands, Executive Director of the Global Fund, said in a statement. 'For the first time, we have a tool that can fundamentally change the trajectory of the HIV epidemic — but only if we get it to the people who need it most.' When antiretroviral drugs first came on the market, they took years to reach Africa. Millions of people died and many more like Concillia suffered while injustice denied them access to life-saving treatment. Now, low- and middle-income countries will have access to this medicine in a timeline that's similar to wealthy countries. It's a massive win for equity and a sign that things are changing for the better. High Hopes For Coartem Baby As Africa prepared for peak malaria season this year, thousands of life-saving bed nets were collecting dust in warehouses across Kenya and Ghana. The nets had already been purchased, but the Trump administration's dismantling of USAID prevented them from being distributed. Malaria is another underreported health crisis that claims a life nearly every minute. Most of the victims are children under the age of five. Symptoms progress quickly and the disease prey's off developing and weakened immune systems. Newborns and small infants have an especially difficult time metabolizing malaria medicine, making it harder for doctors to determine appropriate dosages, which can lead to treatment delays. For the first time, a medicine that's designed specifically to treat newborns and infants with malaria has been approved. Coartem Baby, which is produced by Novartis, can now be used on infants weighing less than roughly 10 lbs. The medicine, which received the green light from Switzerland's therapeutic products regulator is expected to be approved soon in eight African countries — Burkina Faso, Côte d'Ivoire, Kenya, Malawi, Mozambique, Tanzania, Uganda, and Nigeria, which has the highest total annual malaria deaths of any country. The treatment is expected to be sold at a not-for-profit price, making it accessible to more people. 'When there is a medical need that we can address through the science and technologies that we have, we see that as a call to action,' Lutz Hegemann, president of global health at Novartis, told Semafor. The AI Drug Revolution It often costs over $1 billion to bring a new drug to market. Imagine the time and money artificial intelligence could save by predicting a drug's success with near-perfect accuracy. That's exactly what the team at Alphabet's Ismorphic Labs is working on. The company, which was founded by Nobel Prize winner Demis Hassabis, is leveraging artificial intelligence to develop new cancer drugs. Using AlphaFold, a program that predicts protein structures, the company is now able to model how these structures will interact with other molecules. Last year, Ismorphic Labs signed research deals with Novartis and Eli Lilly, and this spring the company raised an additional $600 million in its first-ever external funding round. 'One day we hope to be able to say — well, here's a disease, and then click a button and out pops the design for a drug to address that disease. All powered by these amazing AI tools,' Ismorphic Labs President Colin Murdoch recently told Fortune. The company is not alone. Others like Insilico, Recursion, and Xaira Therapeutics are all working on leveraging AI to accelerate drug discovery and bring new tools to market faster and cheaper. These companies have the potential to help create a future where all preventable and treatable diseases are exactly that — preventable and treatable. But only if these innovations reach people like Concillia. Global experts warn that equity, not just evolution, is needed to ensure new developments reach everyone, everywhere. 'The very last thing that we want to see happen as part of this leap forward with technology is the propagation or amplification of inequities and biases in the social fabric of countries around the world,' Alain Labrique, the WHO's director for digital health and innovation recently warned.


New York Times
an hour ago
- New York Times
As Trump Administration Plans to Burn Contraceptives, Europeans Are Alarmed
The Trump administration's plans to incinerate $9.7 million in birth control pills and other contraceptives stored in a Belgian warehouse have left European governments struggling as they try to prevent the destruction. When the Trump administration abruptly defunded and dismantled the United States Agency for International Development, or U.S.A.I.D, earlier this year, millions of contraceptives it had purchased were stuck in Geel, Belgium. The pills, intrauterine devices and hormonal implants were destined for clinics in the poorest countries in Africa. With the contraceptives in limbo, the contractor managing the supply explored selling it to outside organizations, including the United Nations' main sexual and reproductive health agency, the U.N. Population Fund. The nonprofit MSI Reproductive Choices offered to take over the warehousing and redistribute the contraceptives at no cost to the United States. But last month it emerged that the U.S. government had instead decided to burn the supplies, at a cost to the government of more than $160,000 in transport and incineration fees. 'U.S.A.I.D. was allegedly dismantled to prevent future wastage and to deliver value for money for the American people,' said Sarah Shaw, the associate director of advocacy at MSI Reproductive Choices. 'It's just egregious that they're willing to waste $9 million worth of contraceptives that are so desperately needed.' She added, 'Women are going to die because they've not had access to those contraceptives.' Want all of The Times? Subscribe.